Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Nuchev Pty Ltd Business Overview & Revenue Model
Nuchev Pty Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.27M | 22.94M | 11.34M | 8.79M | 9.72M | 10.90M |
| Gross Profit | 7.17M | 10.86M | 3.63M | 1.90M | 2.78M | 3.20M |
| EBITDA | -4.18M | -3.73M | -7.18M | -8.57M | -10.88M | -12.40M |
| Net Income | -4.58M | -3.82M | -7.32M | -8.81M | -11.11M | -13.27M |
Balance Sheet | ||||||
| Total Assets | 17.39M | 17.39M | 20.09M | 15.32M | 17.75M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 3.11M | 3.61M | 7.61M | 7.49M | 5.13M | 14.53M |
| Total Debt | 529.14K | 392.63K | 322.85K | 284.14K | 154.12K | 286.33K |
| Total Liabilities | 6.63M | 6.16M | 5.34M | 2.51M | 1.92M | 1.62M |
| Stockholders Equity | 10.76M | 11.23M | 14.75M | 12.82M | 15.83M | 26.69M |
Cash Flow | ||||||
| Free Cash Flow | -3.62M | -3.93M | -3.74M | -3.38M | -11.62M | -9.86M |
| Operating Cash Flow | -3.48M | -3.74M | -3.73M | -3.26M | -11.61M | -9.49M |
| Investing Cash Flow | -169.48K | -138.16K | -2.19M | -126.83K | -914.20K | 411.90K |
| Financing Cash Flow | 1.81M | -115.53K | 6.06M | 5.78M | -118.28K | 14.16M |
Nuchev Pty Ltd Technical Analysis
Nuchev Pty Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | AU$37.63M | 22.20 | -53.68% | ― | -15.07% | 29.45% | |
41 Neutral | AU$5.74M | -0.92 | -92.72% | ― | 39.53% | 49.99% | |
40 Underperform | AU$20.39M | -2.06 | -41.69% | ― | 102.21% | 69.47% | |
40 Underperform | AU$31.87M | -0.37 | 19.78% | ― | 1.03% | -52.56% | |
40 Underperform | AU$24.28M | -5.27 | -19.17% | ― | 13.92% | 36.28% |
Nuchev Pty Ltd Corporate Events
Nuchev Limited has notified the market of the issue of 767,442 unquoted share rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 16 March 2026 and reflect the company’s ongoing use of equity incentives to reward and retain staff, with potential dilution for existing shareholders if the rights vest and convert into ordinary shares.
The most recent analyst rating on (AU:NUC) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev has entered a distribution agreement with H&S Global to expand its role across the Brauer, Skin Physics and Rapid Loss brands, shifting from an agency-style arrangement to a full distribution model. The move gives Nuchev greater control over brand execution, pricing and market development, while positioning it more deeply in attractive health, wellness and beauty segments.
Under the new structure, Nuchev will book gross sales and take responsibility for inventory and receivables for these brands, increasing working capital needs but improving margin capture and operating leverage as volumes scale. Management frames the change as a key step in its strategy to build a scalable commercial platform, support margin expansion and move the business toward sustainable profitability, reinforcing the company’s partnership with H&S and its broader growth ambitions.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has reiterated its strategy of building trusted nutrition brands that families can rely on across multiple life stages, highlighting a disciplined focus on science-based product development and high product quality. The company underscored that consistent execution and responsible capital management are central to sustaining brand strength, driving repeat purchases and supporting long-term growth and value for stakeholders.
While specific financial figures for the half year to 31 December 2025 were not disclosed, the release positions Nuchev’s core pillars of brand trust, quality and execution as the key levers for future performance. This strategic emphasis is intended to reinforce the company’s market positioning in premium nutrition and signal a continued commitment to sustainable portfolio value in a competitive sector.
The most recent analyst rating on (AU:NUC) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev reported a 12% rise in half-year revenue to $12.4 million and higher gross profit, driven mainly by its Australian retail channel and supported by practitioner and international markets, despite timing variability in shipments to Vietnam and China. Gross margin eased to 46.2% and EBITDA loss widened to $2.1 million as the company continued to invest in marketing, brand development and organisational capability, remaining debt-free with $3.1 million in cash and a focus on working capital discipline.
Management emphasised that the larger statutory net loss of $2.34 million reflects its deliberate investment phase and the operating scale needed to support future growth. The company is prioritising stronger execution across channels, improving revenue quality and portfolio mix, and advancing new product development to position the business for sustainable profitability and long-term expansion in its core goat milk nutrition markets.
The most recent analyst rating on (AU:NUC) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has reported a 12% increase in revenue to $12.38 million for the half-year ended 31 December 2025, but its net loss after tax widened by 48.2% to $2.34 million, reflecting higher costs or investment outlays despite growing sales. The company did not declare any dividend for the period, and net tangible assets per share dropped from 6.17 cents to 4.29 cents year-on-year, indicating balance sheet pressure that may concern shareholders and highlight the need for improved profitability and capital efficiency.
The group’s net assets fell to $10.76 million while intangibles remained substantial at just over $4.09 million, underlining the importance of brand and other non-physical assets in its business model. With total shares on issue rising to 155.6 million and no changes in control of entities or new joint ventures, Nuchev’s latest half-year update points to a company still in a growth and investment phase, where sustained revenue gains will need to translate into earnings to strengthen investor confidence.
The most recent analyst rating on (AU:NUC) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev reported second-quarter FY26 group sales revenue of $5.3 million, down 19% quarter-on-quarter and 13% year-on-year, with steady performance in its core Oli6 retail business offset by a sharp 48% quarterly decline in practitioner-channel revenue amid softer trading conditions. Despite weaker international sales due to shipment timing and delayed launches, the company generated a net operating cash inflow of $0.8 million, ended the quarter with $3.1 million in cash and no debt, and highlighted new product development across both consumer and practitioner lines as a key driver for future portfolio expansion and scale in ANZ and overseas markets.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has disclosed a change in director Elizabeth Jean Smith’s interests following the exercise of unquoted share rights under the company’s Equity Incentive Plan, which was approved at the November 2024 AGM. Smith has received 278,750 ordinary shares in lieu of director fees valued at A$35,680, increasing her holding from no ordinary shares to 278,750, while her unquoted share rights decreased from 491,017 to 212,267, reflecting the vesting and conversion of incentives into equity and further aligning her interests with shareholders.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced a change in the interests of director Craig Silbery, following the exercise of unquoted share rights under the company’s Equity Incentive Plan. Silbery acquired 474,746 ordinary shares on 22 January 2026 through the conversion of vested share rights issued in lieu of directors’ fees, increasing his direct holding to 5,560,116 ordinary shares while reducing his unquoted share rights to 350,990. The transaction, approved under the company’s previously endorsed incentive framework, further aligns the director’s remuneration with shareholder interests and reflects ongoing use of equity-based compensation at the company.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has reported a change in director Ben Dingle’s interests following the exercise of unquoted share rights granted under the company’s Equity Incentive Plan in lieu of director fees. Dingle converted vested share rights valued at $61,325 into 479,102 ordinary shares, increasing his direct holding to 479,102 shares while maintaining an additional 37,853,680 shares held indirectly via 402339 Pty Ltd as trustee for the Whiti Trust, with the transaction occurring outside a closed period and reflecting ongoing alignment of director compensation with shareholder equity.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has issued 1,232,598 fully paid ordinary shares without a prospectus under the Corporations Act’s disclosure exemptions, confirming that it remains compliant with its continuous and financial reporting obligations and that there is no undisclosed price-sensitive information requiring release. The cleansing notice supports secondary trading of the newly issued shares by assuring investors that the company’s disclosure record is current, thereby facilitating capital management while maintaining transparency for shareholders and the broader market.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has applied to the ASX for quotation of 1,232,598 new ordinary fully paid shares, to be traded under its existing ticker NUC. The new securities, issued on 22 January 2026 following the exercise or conversion of existing options or convertible instruments, will increase the company’s free float and potentially enhance liquidity for shareholders, reflecting ongoing capital structure activity but without disclosing any broader strategic change in this notice.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has appointed Matt Parker as Interim Chief Financial Officer for six months starting 6 January 2026, bringing more than 25 years of financial and commercial leadership across FMCG, healthcare, manufacturing, retail and civil construction, including previous CFO and company secretary roles at several ASX-listed companies. The appointment signals a strengthening of Nuchev’s financial leadership as it continues to grow its nutritional and wellness portfolio across Australia, New Zealand, China and Vietnam, potentially supporting tighter financial governance and execution during a period of ongoing expansion in highly competitive consumer and practitioner-focused markets.
The most recent analyst rating on (AU:NUC) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.